Bayer Files Application For First Chronic Thromboembolic Pulmonary Hypertension Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Bayer has filed for the approval of riociguat, the first chronic thromboembolic pulmonary hypertension, or CTEPH drug, in Japan.